Abstract
Viral vector-based gene therapies are bringing life-changing treatments to patients. One investigational therapy in development is a novel hSGSH gene replacement therapy for the treatment of Mucopolysaccharidosis type IIIA (MPS IIIA), which uses an AAV capsid to deliver a functional gene. If this therapy is approved, a scalable upstream production process is needed to provide the necessary manufacturing capacity to allow it to reach patients. In a recent webinar, new insights into scaling up production of high titer and high-quality viral vectors at clinical and commercial scales were discussed. Some key experimental results are highlighted here.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
